GHRP-6 Research Overview (also known as Growth Hormone Releasing Peptide-6, GHRP-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2)
A synthetic hexapeptide growth hormone releasing peptide similar to GHRP-2 but with significantly stronger appetite-stimulating effects due to more robust ghrelin receptor activation. Studied for GH release, muscle repair support, and applications involving growth or appetite stimulation research.
What Is GHRP-6?
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide and the original member of the GHRP family of GH secretagogues. As a potent ghrelin receptor (GHSR-1a) agonist, it stimulates strong pulsatile GH release from the anterior pituitary. It has the most pronounced appetite-stimulating effect among the GHRPs — a consequence of its robust ghrelin receptor activation in hypothalamic feeding centers — which makes it particularly relevant for research in GH-deficient states and conditions of poor appetite or malnutrition.
Mechanism and Gastroprotective Effects
GHRP-6 agonizes ghrelin receptors on pituitary somatotrophs while reducing somatostatin tone. An important additional property is its gastroprotective activity: studies have shown GHRP-6 accelerates gastric ulcer healing, reduces intestinal inflammation, and protects against NSAID-induced gastric injury through ghrelin receptor activation in the GI tract.
Cardioprotective Research
GHRP-6 has demonstrated cardioprotective properties in ischemia-reperfusion injury models — reducing infarct size and improving cardiac function recovery through GHS-R1a receptors on cardiomyocytes and CD36-dependent anti-apoptotic signaling pathways. This cardioprotective property is shared with Hexarelin.
Quick Reference
| Literature-Reported Dose Range | 100mcg per injection |
| Literature-Reported Frequency | 3x daily, at least 4 hours apart |
| Literature-Reported Cycle Length | 8-12 weeks |
| Literature-Reported Washout | 4-8 weeks between cycles |
| Storage | Refrigerate at 2-8°C after reconstitution |
| Timing | 2-3 hours after eating, 30 minutes before next meal. Bedtime dose most important. |
Research Indications
Hormonal
Growth Hormone Release
Potent GH secretagogue with dose-dependent release demonstrated in human clinical studies via GHS-R1a activation
Synergy with GHRH Peptides
Simultaneous stimulation with GHRH-class peptides produces synergistic GH response 2-3x greater than either alone
IGF-1 Elevation
Sustained GH release increases downstream IGF-1 for anabolic and tissue repair support
Cardiovascular
Cardioprotection
In preclinical models, rescued >70% of ischemic myocardium in pigs. 100% survival in canine acute MI model vs 50% in controls. Human efficacy under investigation.
Doxorubicin Cardiotoxicity Prevention
Completely prevented cardiac dysfunction in doxorubicin-treated rats through prosurvival pathway activation (2024 preclinical study)
Anti-Fibrotic Cardiac Effects
Reduces cardiac fibrosis by increasing MMP-2/MMP-9 activities and decreasing TIMP-1 expression
Tissue Repair
Wound Healing
Topical GHRP-6 significantly accelerated wound closure and prevented hypertrophic scar formation in 90.5% of treated wounds
Neuroprotection
Combined with EGF, improved neurological outcomes and survival in Phase I/II acute ischemic stroke trial (2024)
Multi-Organ Cytoprotection
Pharmacological preconditioning reduces kidney, lung, and intestinal damage during ischemia/reperfusion injury
Muscle Growth
Lean Mass Support
GH and IGF-1 elevation supports muscle protein synthesis and body composition improvements over 8-12 week protocols
Recovery Enhancement
Pulsatile GH release supports exercise recovery, sleep quality, and tissue repair processes
Appetite Stimulation
Strong ghrelin-mediated appetite increase supports caloric surplus for muscle growth phases
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| GH Release (Standard) | 100mcg | 3x daily on empty stomach | SubQ |
| GH Release (Moderate) | 200mcg | 2-3x daily on empty stomach | SubQ |
| Combined with GHRH Peptide | 100mcg + 100mcg CJC-1295 | 2-3x daily | SubQ |
Timing
2-3 hours after eating, 30 minutes before next meal. Bedtime dose most important. Typical onset: gH pulse within 15-30 min. Appetite increase within 15-20 min. Body composition changes 4-8 weeks.
Peptide Interactions
Strong synergy - GHRP-6 amplifies the GH pulse initiated by CJC-1295 through complementary receptor pathways (GHS-R1a + GHRH-R). Combined GH response is 2-3x greater than either alone. Well-established clinical combination.
DAC version provides sustained GHRH stimulation (6-8 day half-life) which may lead to continuous GH elevation ("GH bleed") rather than pulsatile release when combined with GHRP-6. Pulsatile GH is preferred for mimicking natural physiology and avoiding receptor desensitization. Non-DAC CJC-1295 (Mod GRF 1-29) preferred for combination protocols.
Both target GHS-R1a for GH release. Combination is redundant for GH stimulation—no additional GH benefit. Choose based on profile: GHRP-6 offers appetite stimulation and broader cytoprotective effects (via CD36 antagonism), while ipamorelin provides more selective GH release with minimal cortisol/prolactin elevation. Not unsafe, but therapeutically redundant.
Both are GHRP-class secretagogues acting on GHS-R1a. Hexarelin is a GHRP-6 derivative with 2-methyl-Trp substitution providing higher potency. Combination is redundant for GH stimulation and may amplify cortisol/prolactin side effects without proportional GH benefit. Choose one based on desired potency profile.
MK-677 (ibutamoren) is an oral GHS-R1a agonist with a ~24-hour half-life, providing continuous ghrelin receptor stimulation. Combining with GHRP-6 creates redundant receptor activation with significantly amplified side effects (appetite, cortisol, prolactin elevation) without proportional GH benefit. Avoid combination due to side effect burden from sustained + pulsed receptor stimulation.
Different mechanisms with no known interactions. BPC-157 focuses on tissue repair through distinct pathways. May complement recovery protocols.
Different mechanisms - TB-500 works through actin regulation and angiogenesis while GHRP-6 acts through GH release and ghrelin signaling. No known negative interactions.
Exogenous HGH combined with GHRP-6 may produce excessive GH/IGF-1 levels. If combining, use lower doses of each and monitor IGF-1 levels. GHRP-6 stimulates endogenous GH which is preferable to exogenous for pulsatile release.
GHRH analog + GHRP creates the classic synergistic combination. Sermorelin stimulates via GHRH receptor while GHRP-6 acts through GHS-R1a for amplified pulsatile GH release.
GHRP-6 may increase blood glucose and reduce insulin sensitivity. Diabetic patients or those using insulin should monitor glucose closely and adjust doses under medical supervision.
Reported Research Timeline
01Immediately: Intense hunger within 15-20 minutes, lasting 1-3 hours
02Week 1–2 (reported in cited studies): improved sleep quality, increased appetite
03Week 4–6 (reported in cited studies): body composition changes (lean mass increase, fat reduction)
04Week 8–12 (reported in cited studies): peak effects on recovery and body composition
05Hunger intensity may diminish after several weeks but persists throughout use
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Proven safe in human Phase I dose-escalation trial with IV administration
Strong appetite increase is expected (ghrelin receptor activation) - not an adverse effect
Transiently elevates cortisol and prolactin, particularly at doses above 100mcg
May increase blood glucose and reduce insulin sensitivity with prolonged use - monitor if diabetic or insulin resistant
Avoid use in active cancer - GH/IGF-1 elevation may promote tumor growth
Must inject on empty stomach - food significantly blunts GH response
Less selective than ipamorelin (elevates cortisol, prolactin, and appetite)
No pharmacological interaction with beta-blocker metoprolol demonstrated in clinical studies
Prolonged continuous use may lead to ghrelin receptor (GHS-R1a) desensitization, reducing GH response. Cycling (8-12 weeks on, 4-8 weeks off) recommended to maintain efficacy.
Seek Medical Attention If:
Persistent water retention or edema
Signs of carpal tunnel syndrome (numbness, tingling in hands)
Significant blood glucose elevation or insulin resistance symptoms
Gynecomastia or nipple sensitivity (prolactin-related)
Joint pain beyond mild initial adjustment
Any signs of allergic reaction
Quality Indicators
Verified Marker
White Lyophilized Powder
Pure GHRP-6 appears as white to off-white lyophilized powder or puck
Verified Marker
Clear Reconstituted Solution
Properly reconstituted solution should be crystal clear with no particles
Verified Marker
Certificate of Analysis
Should include HPLC purity (>98%), sequence confirmation, and endotoxin testing
Acceptable Range
Appetite Response Test
Noticeable hunger within 20 minutes of first injection indicates GHS-R1a activation and suggests active peptide. However, this is a basic indicator only—HPLC testing is still required to confirm purity and sequence integrity.
Quality Concern
Discolored or Cloudy Solution
Yellow or cloudy solution indicates degradation - do not use
Research Citations
- Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects
Berlanga-Acosta, J., Abreu-Cruz, A., Herrera, D.G.B., et al., 2017, Clinical Medicine Insights: Cardiology - Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms
Berlanga-Acosta, J., Cibrian, D., Valiente-Mustelier, J., et al., 2024, Frontiers in Pharmacology - Combination therapy of Epidermal Growth Factor and Growth Hormone-Releasing Hexapeptide in acute ischemic stroke: a phase I/II non-blinded, randomized clinical trial
Hernández-Bernal, F., et al., 2024, Frontiers in Neurology - Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation
Pandya, N., DeMott-Friberg, R., Bowers, C.Y., Barkan, A.L., Jaffe, C.A., 1998, Journal of Clinical Endocrinology & Metabolism - Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds
Mendoza Marí, Y., Fernández Mayola, M., Aguilera Barreto, A., et al., 2016, Plastic Surgery International - Ipamorelin, the first selective growth hormone secretagogue
Raun, K., Hansen, B.S., Johansen, N.L., et al., 1998, European Journal of Endocrinology - The Safety and Efficacy of Growth Hormone Secretagogues
Sigalos, J.T., Pastuszak, A.W., 2018, Sexual Medicine Reviews - Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation
Zhao X, Pan K, Li R, 2025, J Nanobiotechnology - N-aminoimidazolidin-2-one peptidomimetics
Doan ND, Hopewell R, Lubell WD, 2014, Org Lett - Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms
Berlanga-Acosta J, Cibrian D, Valiente-Mustelier J, 2024, Front Pharmacol - Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis
Wang L, Berlanga-Acosta J, Yu H, 2026, Int Immunopharmacol - Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure
Cibrián D, Ajamieh H, Berlanga J, 2006, Clin Sci (Lond)
Research Focus
Growth hormone release, Appetite stimulation, Muscle mass, Gastroprotection, Cardioprotection
Verified Vendors Carrying GHRP-6
Frequently Asked Questions
What should researchers watch for with GHRP-6?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with GHRP-6?
Immediately: Intense hunger within 15-20 minutes, lasting 1-3 hours
How is GHRP-6 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →